AU2014331796B2 - Spray dry formulations - Google Patents

Spray dry formulations Download PDF

Info

Publication number
AU2014331796B2
AU2014331796B2 AU2014331796A AU2014331796A AU2014331796B2 AU 2014331796 B2 AU2014331796 B2 AU 2014331796B2 AU 2014331796 A AU2014331796 A AU 2014331796A AU 2014331796 A AU2014331796 A AU 2014331796A AU 2014331796 B2 AU2014331796 B2 AU 2014331796B2
Authority
AU
Australia
Prior art keywords
groups
substituted
unsubstituted
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014331796A
Other languages
English (en)
Other versions
AU2014331796A1 (en
Inventor
Lawrence S. ZISMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PULMOKINE Inc
Gilead Sciences Inc
Original Assignee
PULMOKINE Inc
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PULMOKINE Inc, Gilead Sciences Inc filed Critical PULMOKINE Inc
Publication of AU2014331796A1 publication Critical patent/AU2014331796A1/en
Priority to AU2020202556A priority Critical patent/AU2020202556A1/en
Application granted granted Critical
Publication of AU2014331796B2 publication Critical patent/AU2014331796B2/en
Priority to AU2022203611A priority patent/AU2022203611A1/en
Assigned to GILEAD SCIENCES, INC., PULMOKINE, INC. reassignment GILEAD SCIENCES, INC. Request for Assignment Assignors: ZISMAN, LAWRENCE
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014331796A 2013-10-11 2014-10-10 Spray dry formulations Active AU2014331796B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020202556A AU2020202556A1 (en) 2013-10-11 2020-04-16 Spray dry formulations
AU2022203611A AU2022203611A1 (en) 2013-10-11 2022-05-27 Spray dry formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889887P 2013-10-11 2013-10-11
US61/889,887 2013-10-11
PCT/US2014/060039 WO2015054574A1 (en) 2013-10-11 2014-10-10 Spray dry formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020202556A Division AU2020202556A1 (en) 2013-10-11 2020-04-16 Spray dry formulations

Publications (2)

Publication Number Publication Date
AU2014331796A1 AU2014331796A1 (en) 2016-04-28
AU2014331796B2 true AU2014331796B2 (en) 2020-05-07

Family

ID=52813663

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014331796A Active AU2014331796B2 (en) 2013-10-11 2014-10-10 Spray dry formulations
AU2020202556A Abandoned AU2020202556A1 (en) 2013-10-11 2020-04-16 Spray dry formulations
AU2022203611A Abandoned AU2022203611A1 (en) 2013-10-11 2022-05-27 Spray dry formulations

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020202556A Abandoned AU2020202556A1 (en) 2013-10-11 2020-04-16 Spray dry formulations
AU2022203611A Abandoned AU2022203611A1 (en) 2013-10-11 2022-05-27 Spray dry formulations

Country Status (8)

Country Link
US (2) US9925184B2 (OSRAM)
EP (1) EP3054937B1 (OSRAM)
JP (3) JP6483714B2 (OSRAM)
CN (2) CN106132403B (OSRAM)
AU (3) AU2014331796B2 (OSRAM)
CA (1) CA2926793C (OSRAM)
ES (1) ES2959419T3 (OSRAM)
WO (1) WO2015054574A1 (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CA2897651C (en) 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
EA031604B1 (ru) 2013-10-25 2019-01-31 Инсмед Инкорпорейтед Трепростинильные соединения, композиции и способы их использования
EP3221291B1 (en) 2014-11-18 2021-03-31 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2017132601A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry powder inhaler
IL262720B2 (en) * 2016-05-05 2024-06-01 Liquidia Tech Inc Dry powder treprostinil for the treatment of pulmonary hypertension
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
CA3027970A1 (en) * 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency
CN110087653A (zh) 2016-10-27 2019-08-02 普尔莫凯恩股份有限公司 用于治疗肺高血压的组合疗法
CN115919780A (zh) 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
US20210038510A1 (en) * 2018-02-08 2021-02-11 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
CN112789033A (zh) * 2018-10-02 2021-05-11 学校法人名城大学 吸入粉末剂、其评价方法及其用途
KR20220002600A (ko) * 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
JP2022532431A (ja) 2019-05-16 2022-07-14 エアロベイト セラピューティクス， インコーポレイテッド イマチニブ製剤、その製造および使用
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
WO2021201258A1 (ja) * 2020-04-01 2021-10-07 株式会社ＳｔａｔｅＡｒｔ 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法
US20240325390A1 (en) * 2020-11-23 2024-10-03 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
US20240228462A1 (en) 2021-05-07 2024-07-11 Gb002, Inc. Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2- yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
CN119677525A (zh) 2022-08-10 2025-03-21 Gb002股份有限公司 用于治疗动脉性肺动脉高压（pah）的酪氨酸激酶抑制剂和激活素2型受体拮抗剂的组合疗法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018243A1 (en) * 1999-08-25 2004-01-29 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20130137660A1 (en) * 2006-11-15 2013-05-30 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118401A (en) 1977-10-19 1978-10-03 American Hoechst Corporation Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor
JPS5488231A (en) 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5648369A (en) 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
SK27198A3 (en) 1995-08-30 1998-09-09 Bayer Ag Acylaminosalicylic acid amides and their uses as pesticides
JPH09268169A (ja) 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
ATE364374T1 (de) 1997-08-11 2007-07-15 Pfizer Prod Inc Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6458849B1 (en) 1999-09-23 2002-10-01 G.D. Searle & Co. use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
HUP0203323A3 (en) 1999-10-19 2004-01-28 Merck & Co Inc Tyrosine kinase inhibitors and pharmaceutical compositions containing them
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
CA2486187C (en) 2002-05-23 2013-02-19 Cytopia Pty Ltd. Kinase inhibitors
US7122550B2 (en) 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
US6776309B2 (en) 2002-05-23 2004-08-17 Ben Z. Cohen Medically accurate pump system
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
TW200410688A (en) 2002-06-26 2004-07-01 Ono Pharmaceutical Co Therapeutics for diseases from vasoconstriction or vasodilatation
EP1545523A1 (en) 2002-07-03 2005-06-29 Astex Technology Limited 3-&-grave;(HETERO) ARYLMETHOXY ! PYRIDINES AND THEIR ANALOGUES ASP38 MAP KINASE INHIBITORS
WO2004006858A2 (en) 2002-07-15 2004-01-22 Myriad Genetics, Inc Compounds, compositions, and methods employing same
AU2003272007A1 (en) 2002-10-25 2004-05-13 The Administrators Of The Tulane Educational Fund Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
FR2858459B1 (fr) 2003-08-01 2006-03-10 Commissariat Energie Atomique Commutateur micro-mecanique bistable, methode d'actionnement et procede de realisation correspondant
AR045731A1 (es) 2003-08-06 2005-11-09 Vertex Pharma Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas
KR101167573B1 (ko) 2003-11-07 2012-07-30 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 개선된 약학적 성질을 갖는 퀴놀리논 화합물의 약학적으로허용가능한 염
ATE497949T1 (de) 2003-12-03 2011-02-15 Ym Biosciences Australia Pty Tubulininhibitoren
JP4808628B2 (ja) 2003-12-03 2011-11-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド アゾール系キナーゼ阻害剤
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
WO2005114219A2 (en) 2004-05-20 2005-12-01 Wyeth Assays to identify irreversibly binding inhibitors of receptor tyrosine kinases
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
JP5075832B2 (ja) 2005-11-10 2012-11-21 バイエル・ファルマ・アクチェンゲゼルシャフト 肺高血圧を処置するためのジアリールウレア
WO2007087575A2 (en) 2006-01-24 2007-08-02 University Of Chicago Compositions and methods for treating pulmonary hypertension
AU2007220047B2 (en) 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
WO2007124382A2 (en) 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
EP2152688A1 (en) 2007-05-04 2010-02-17 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
BRPI0811617A2 (pt) 2007-05-04 2017-06-06 Irm Llc derivados de primidina e composições como inibidores de c-kit e pdgfr quinase.
MX2010002004A (es) 2007-08-22 2010-03-11 Irm Llc Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones con inhibidores de cinasa.
WO2009026204A1 (en) 2007-08-22 2009-02-26 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
MX2010006033A (es) 2007-12-20 2010-07-16 Bayer Schering Pharma Ag 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso.
CA2732789A1 (en) 2008-08-13 2010-02-18 Novartis Ag Treatment of pulmonary arterial hypertension
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010102066A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Dextran polymer powder for inhalation administration of pharmaceuticals
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
US9084976B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
EP2618924A1 (en) 2010-09-24 2013-07-31 Bend Research, Inc. High-temperature spray drying process and apparatus
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
JP6012716B2 (ja) * 2011-05-19 2016-10-25 サヴァラ，インク． 乾燥粉末バンコマイシン組成物および関連する方法
WO2013033167A1 (en) 2011-09-01 2013-03-07 Irm Llc Compounds and compositions as c-kit kinase inhibitors
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP2988738A4 (en) * 2013-01-10 2016-11-09 Pulmokine Inc THERAPEUTIC INDICATIONS OF KINASE INHIBITORS
CA2897651C (en) * 2013-01-10 2021-09-21 Pulmokine, Inc. Non-selective kinase inhibitors
US20150044288A1 (en) 2013-07-31 2015-02-12 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018243A1 (en) * 1999-08-25 2004-01-29 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US20130137660A1 (en) * 2006-11-15 2013-05-30 Ym Biosciences Australia Pty Ltd Inhibitors of kinase activity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PINCHUK, B ET AL.,MARINE DRUGS, vol. 11, (2013-08-26), pages 3209 - 3223, URL: https://www.scienceopen.com/document_file/1feb993a-c198-4bf0-9f23-73597fc1fc49/PubMedC entral/1feb993a-c198-4bf0-9f23-73597fc1fc49.pdf *

Also Published As

Publication number Publication date
US20180193336A1 (en) 2018-07-12
JP6823095B2 (ja) 2021-01-27
AU2020202556A1 (en) 2020-05-07
CN111743901A (zh) 2020-10-09
ES2959419T3 (es) 2024-02-26
CA2926793C (en) 2022-11-22
US20160235742A1 (en) 2016-08-18
WO2015054574A1 (en) 2015-04-16
CN106132403B (zh) 2020-04-28
JP6483714B2 (ja) 2019-03-13
US9925184B2 (en) 2018-03-27
CN106132403A (zh) 2016-11-16
JP2019089830A (ja) 2019-06-13
CN111743901B (zh) 2023-09-12
EP3054937A4 (en) 2017-05-03
JP2016534153A (ja) 2016-11-04
EP3054937A1 (en) 2016-08-17
AU2022203611A1 (en) 2022-06-16
CA2926793A1 (en) 2015-04-16
AU2014331796A1 (en) 2016-04-28
EP3054937B1 (en) 2023-07-26
JP2021063119A (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
AU2014331796B2 (en) Spray dry formulations
AU2023201605B2 (en) Non-selective kinase inhibitors
EP2988738A2 (en) Therapeutic indications of kinase inhibitors
HK40036372B (zh) 喷雾干燥制剂
HK40036372A (en) Spray dry formulations
HK40009913A (en) Non-selective kinase inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: PULMOKINE, INC.

Free format text: FORMER OWNER(S): ZISMAN, LAWRENCE

Owner name: GILEAD SCIENCES, INC.

Free format text: FORMER OWNER(S): ZISMAN, LAWRENCE